Blue Lake Biotechnology, Inc.

Blue Lake and CyanVac's Intranasal COVID-19 Vaccine Shows Promise in Phase 2a Trial

6 months ago

• Blue Lake and CyanVac reported positive Phase 2a clinical trial data for their intranasal COVID-19 vaccine candidate, CVXGA, demonstrating safety and efficacy. • The trial showed a 78% reduction in the risk of symptomatic COVID-19 infection in participants who received CVXGA compared to the placebo group. • CVXGA induced S-protein specific serum antibody responses in both younger (18-64 years) and older adults (65+ years), with good tolerability. • The PIV5-vectored vaccine showed no significant difference in adverse reactions compared to placebo, suggesting a safe and well-tolerated profile.